The pharmaceutical company Double Bond Pharma reports preliminary data from a retrospective analysis of 484 patients who underwent surgery for malignant primary brain tumors in 2020–2025. Median survival was 14.3 months with Temodex versus 9.4 months for standard treatment, a statistically significant difference with a p-value of 0.0048. The results have been submitted to EANS2026. "These findings provide a clear indication of clinical effect," says Igor Lokot, CEO of Double Bond Pharma. "An extension of median survival by nearly five months in an unselected population is a significant result. We are using these data from Temodex as a basis for the continued international development of SI-053."